JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

36.42 1.65

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

36.16

Max

36.97

Schlüsselkennzahlen
By Trading Economics
Einkommen	-22M -102M
Angestellte	258
EBITDA	-30M -109M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+41.41% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	645M 6.3B
Vorheriger Eröffnungskurs	34.77
Vorheriger Schlusskurs	36.42

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Mai 2026, 21:36 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1. Mai 2026, 20:40 UTC

Akquisitionen, Fusionen, Übernahmen

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1. Mai 2026, 18:37 UTC

Wichtige Markttreiber

Senseonic Shares Slide on Underwritten Offering Price

1. Mai 2026, 16:46 UTC

Wichtige Markttreiber

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2. Mai 2026, 19:57 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2. Mai 2026, 15:24 UTC

Ergebnisse

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2. Mai 2026, 12:46 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2. Mai 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1. Mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

1. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. Mai 2026, 20:42 UTC

Ergebnisse

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1. Mai 2026, 19:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. Mai 2026, 19:33 UTC

Market Talk

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1. Mai 2026, 19:18 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1. Mai 2026, 19:13 UTC

Market Talk

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1. Mai 2026, 18:36 UTC

Ergebnisse

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1. Mai 2026, 18:35 UTC

Ergebnisse

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1. Mai 2026, 18:28 UTC

Ergebnisse

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1. Mai 2026, 18:27 UTC

Market Talk

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1. Mai 2026, 18:14 UTC

Akquisitionen, Fusionen, Übernahmen

Barclays Completes Acquisition of Best Egg

1. Mai 2026, 18:04 UTC

Ergebnisse

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1. Mai 2026, 17:43 UTC

Market Talk

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1. Mai 2026, 17:37 UTC

Market Talk

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1. Mai 2026, 17:30 UTC

Market Talk

Ergebnisse

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1. Mai 2026, 17:28 UTC

Market Talk

Ergebnisse

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1. Mai 2026, 17:21 UTC

Market Talk

Ergebnisse

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1. Mai 2026, 17:19 UTC

Market Talk

Wichtige Nachrichtenereignisse

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1. Mai 2026, 16:38 UTC

Market Talk

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1. Mai 2026, 16:23 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1. Mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

41.41% Vorteil

12-Monats-Prognose

Durchschnitt 51.8 USD 41.41%

Hoch 64 USD

Tief 35 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.